As for a combo of Anti-CD47 and Anti-PD1 then I can't see this being the hole grail as downregulation of MHC class I expression is a widespread phenomenon used by tumour cells to escape anti-tumor T-cell mediated immune responses. Then there are other checkpoints http://www.ncbi.nlm.nih.gov/pubmed/26883990 mutations http://www.nejm.org/doi/full/10.1056/NEJMoa1604958#t=article and possible lack of costimulation and other things to keep in mind.
Also M2's aren't the only immunosuppressive cells in a tumour. There are Tregs and MDSCs as well. Then there is tumour derived lactate and stromal density which can help with immune evasion too.
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM